Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00185042 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease
A Phase 2 study of Coronary Heart Disease, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 534
- Enrollment target
- 20
- Study locations
NCT00185042: Completed Phase 2 study of Coronary Heart Disease, sponsored by Daiichi Sankyo.
NCT00185042 is a Phase 2 study of Coronary Heart Disease that has completed, run by Daiichi Sankyo. The registered enrollment target is 534 participants, below the 1,460-participant average among 19 other Coronary Heart Disease trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00185042, a Phase 2 study of Coronary Heart Disease, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 534 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to learn if CS-505 is safe and effective for slowing down or possibly reversing the buildup of tissue, cells and fatty deposits (plaque) in the blood vessels of the heart (coronary artery atherosclerosis).
Conditions Studied
Interventions
- DRUG Pactimibe, CS-505
Study Locations (20)
Florida
- - Clearwater
- - Gainsville
- - Hudson
- - Jacksonville
- - Melbourne
- - Miami
- - Pensacola
- - Port Charlotte
- - Sarasota
- - Tallahassee
- - Tampa
Alabama
- - Birmingham
- - Huntsville
- - Mobile
California
- - Los Angeles
- - San Diego
Arizona
- - Phoenix
Colorado
- - Fort Collins
Connecticut
- - Bridgeport
Delaware
- - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 534 participants |
| Start Date | 2002-11 |
| Est. Completion | 2005-07 |
| Phase | Phase 2 |
What the finished NCT00185042 record still lists
NCT00185042 is an interventional study that assigns participants to a tested intervention. The registered 534 participants enrollment target is mid-sized for trials with a published cap, below the 1,460-participant average among 19 other Coronary Heart Disease trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Coronary Heart Disease appearing as the primary indexed condition, and to 1 intervention - of which Pactimibe, CS-505 is the first listed.
NCT00185042 names 20 study sites across 7 states, led by Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT00185042 about?
NCT00185042 is a clinical study titled "Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease". The purpose of this study is to learn if CS-505 is safe and effective for slowing down or possibly reversing the buildup of tissue, cells and fatty deposits (plaque) in the blood vessels of the heart (coronary artery atherosclerosis).
What is the current status of trial NCT00185042?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 534 participants. The study started on 2002-11. Estimated completion is 2005-07.
What conditions does trial NCT00185042 study?
This clinical trial studies the following conditions: Coronary Heart Disease.
What interventions are being tested in trial NCT00185042?
The interventions under investigation include: Pactimibe, CS-505 (DRUG).
Who is sponsoring clinical trial NCT00185042?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00185042 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00185042's enrollment target sits among peer trials
534 8th of 19 higher than 12 of 19 other Coronary Heart Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
COMPLETED · Phase 2
-
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
COMPLETED · Phase 2
-
Project 3: ACHIEVE- CHD
RECRUITING · NA
-
Thiamine Intervention and Coronary Artery Bypass Grafting
RECRUITING · Early Phase 1
-
Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients
RECRUITING · NA
-
Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- NCT06128551 · 534 participants · Phase 1
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- NCT07091617 · 535 participants · NA
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia